



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
PO Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08 809,650	06/13/1997	GEORGES Bahr	2121-128PCT	7849
2292	7590	07/28/2003		
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			EXAMINER	
			SCHEINER, LAURIE A	
		ART UNIT	PAPER NUMBER	
		1648		

DATE MAILED: 07/28/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. <b>08/809,650</b>	Applicant(s) <b>Bahr, G.</b>
Examiner <b>Laurie Scheiner</b>	Art Unit <b>1648</b>



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

1)  Responsive to communication(s) filed on Mar 18, 2003

2a)  This action is **FINAL**.      2b)  This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

### Disposition of Claims

4)  Claim(s) 25, 26, and 28-34 is/are pending in the application.

4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5)  Claim(s) \_\_\_\_\_ is/are allowed.

6)  Claim(s) 25, 26, and 28-34 is/are rejected.

7)  Claim(s) \_\_\_\_\_ is/are objected to.

8)  Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are a)  accepted or b)  objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)  The proposed drawing correction filed on \_\_\_\_\_ is: a)  approved b)  disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)  The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. §§ 119 and 120

13)  Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)  All b)  Some\* c)  None of:

1.  Certified copies of the priority documents have been received.

2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\*See the attached detailed Office action for a list of the certified copies not received.

14)  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

a) The translation of the foreign language provisional application has been received.

15)  Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

### Attachment(s)

1)  Notice of References Cited (PTO-892)

4)  Interview Summary (PTO-413) Paper No(s)

2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)

5)  Notice of Informal Patent Application (PTO-152)

3)  Information Disclosure Statement(s) (PTO-1449) Paper No(s)

6)  Other

Art Unit: 1648

Claims 25, 26 and 28-34 are pending. Appellants' brief filed in triplicate on March 18, 2003 is acknowledged. In response, the finality of the last Office action is withdrawn.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-30 of U.S. Patent No. 5,932,208 are obvious over instant claims 25, 26, 28-32 and 34. Therefore, claims 25, 26, 28-32 and 34 are rejected under the judicially created doctrine of obviousness-type double patenting so as to prevent an improper extension of patent rights. It is noted that instant claims are read with the elected murabutide limitation for purposes of determining the obviousness-type double patenting rejection. Although the conflicting claims are not identical, they are not patentably distinct from each other because the patented (genus) claims are made obvious by the more narrow instant (specie) claims. That is, a two way analysis

Art Unit: 1648

is not required, and the methods of instant claims 25, 26, 28, 29 and 34 do not exclude the addition of another molecule.

Claims 25, 26 and 28-34 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The recitation of "as a principal ingredient" is considered to be new matter since support cannot be found in the disclosure as originally filed. Additionally, the specification fails to teach the administering of the murabutide as "a principal ingredient" to a man or animal as claimed. As such, it is not evident that applicants were in possession of the claimed invention at the time of filing due to a lack of an adequate written description. The written description requirement under Section 112, first paragraph, sets forth that the claimed subject matter must be supported by an adequate written description that is sufficient to enable anyone skilled in the art to make and use the invention. The courts have concluded that the specification must demonstrate that the inventor(s) had possession of the claimed invention as of the filing date relied upon. Although the claimed subject matter need not be described identically, the disclosure relied upon must convey to those skilled in the art that applicants had invented the subject matter claimed. *In re Wilder, et al.*, 222 U.S.P.Q. 369 (C.A.F.C. 1984). *In re Werthheim, et al.*, 191 U.S.P.Q. 90 (C.C.P.A. 1976). *In re Driscoll*, 195 U.S.P.Q. 434 (C.C.P.A. 1977). *Utter v. Hiraga*, 6 U.S.P.Q.2d 1709 (C.A.F.C. 1988). *University of California v. Eli Lilly*, 119 F.3d 1559, 43 U.S.P.Q.2d 1398 (Fed. Cir. 1997). *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 U.S.P.Q.2d 1016-1031 (C.A.F.C. 1991). *Fiers v. Sugano*, 25 U.S.P.Q.2d 1601-1607 (C.A.F.C. 1993). *In re Bell*, 26 U.S.P.Q.2d 1529-1532 (C.A.F.C. 1993). *In re Deuel*, 34 U.S.P.Q.2d 1210-1216 (C.A.F.C. 1995). That is, it is well settled that the

Art Unit: 1648

claimed subject matter need not be supported by an explicit, word for word recitation, but something more than a suggestion is needed to satisfy the requirement for an adequate written description. As set forth in Lockwood v. American Airlines Inc., 107 F.3d 1565, 1571-1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997):

It is the disclosures of the applications that count. Entitlement to a filing date does not extend to subject matter which is not disclosed, but would be obvious over what is expressly disclosed. It extends only to that which is disclosed. While the meaning of terms, phrases, or diagrams in a disclosure is to be explained or interpreted from the vantage point of one skilled in the art, all the limitations must appear in the specification. The question is not whether a claimed invention is an obvious variant of that which is disclosed in the specification. Rather, a prior application itself must describe an invention, and do so in sufficient detail that one skilled in the art can clearly conclude that the inventor invented the claimed invention as of the filing date sought. . . [A]ll that is necessary to satisfy the description requirement is to show that one is "in possession" of the invention . . . One shows that one is "in possession" of the invention by describing the invention, with all its claimed limitations, not that which makes it obvious. . . Although the exact terms need not be used in haec verba, . . . the specification must contain an equivalent description of the claimed subject matter. [Citations omitted]

It is not sufficient for purposes of the written description requirement of Section 112 that the disclosure, when combined with knowledge in the art, would lead one to speculate as to modifications that the inventor might have envisioned, but failed to disclose.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 25, 26, 28-30 and 34 are rejected under 35 U.S.C. 102(b) as being anticipated by Schreck et al.

Schreck et al. clearly teach that several muramyl peptides, including murabutide, have been shown to act as safe and efficacious adjuvants in vaccines against viruses. Schreck et al.

Art Unit: 1648

refer to the muramyl peptides as adjuvants, however, they also refer to the same peptides as immunostimulants. Thus, the reference to murabutide as an adjuvant is simply a matter of semantics since the term does not exclude other descriptive terms. That is, murabutide may be characterized as a muramyl peptide, immunostimulant, non-pyrogenic peptide, non-inflammatory inducer, synthetic immunomodulator, stimulator of non-specific resistance to bacterial and parasite infections *in vivo* and *in vitro*, etc. That muramyl peptides may be characterized structurally/functionally as adjuvant does not in anyway distinguish from that which is claimed. That is, the respective method steps of the art and instant claims are the same. Again, it is noted that the specification fails to define the term "principal ingredient", and it is argued that the term does not exclude other necessary, fundamental or synergistic ingredients. Again, improperly imposed semantics cannot make marginal the methods set forth by Schreck et al.

Claims 25, 26, 28-30 and 34 are rejected under 35 U.S.C. 102(b) as being anticipated by Masihi et al.

Masihi et al. clearly teach that which is claimed. Murabutide increased the number of granulocyte-macrophage progenitors in the spleen of mice.

Applicants have argued in their Answer that the examiner has failed to put forth on the record the particular part of Schreck et al. teaching that by administering their disclosed muramyl peptides, inhibition of immunodeficiency retroviruses can be achieved.

The examiner contends that applicants have conceded that the method of the invention does not exclude methods of prophylaxis, and thus also encompasses treatment of non-infected cells. Well settled patent law establishes that a preamble is not given patentable weight. Thus, there is no requirement for inhibition of the AIDS virus replication, and there is no requirement for virally infected cells prior to treatment. The reference has met the method steps as claimed

Art Unit: 1648

since the claim (25) requires administering an effective amount of murabutide to an animal. The claim does not require that the animal is infected; thus, the effective amount falls within a range, which is also taught by the reference.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laurie Scheiner, whose telephone number is (703) 308-1122. Due to a flexible work schedule, the examiner's hours typically vary each day. However, the examiner can normally be reached Monday thru Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242, (703) 305-3014, (703) 872-9306 or (703) 872-9307. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 746-5226.

  
Laurie Scheiner/LAS  
July 25, 2003

  
LAURIE SCHEINER  
PRIMARY EXAMINER